Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes

• Main Authors: Samrat Chakraborty (Author), Zewdu Yilma Dlie (Author), Somdyuti Chakraborty (Author), Somdatta Roy (Author), Biswajit Mukherjee (Author), Shila Elizabeth Besra (Author), Saikat Dewanjee (Author), Alankar Mukherjee (Author), Probir Kumar Ojha (Author), Vinay Kumar (Author), Ramkrishna Sen (Author)
• Formato: Livro
• Publicado em: Elsevier, 2020-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Site-specific delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes should be a focus for potential therapeutic management of hepatocellular carcinoma (HCC). The aptamer TLS 9a with phosphorothioate backbone modifications (L5) has not been explored...